Based on these studies, and taken in conjunction with the promise STING agonists have shown as cancer immunotherapy agents, we posited that activation of the STING pathway in bone cancer may be a unique synergistic approach to concurrently promote antitumor immunity, suppress bone destruction, and provide pain control. The gene discussed is STING1; the disease is cancer.